BSD Medical Closes Previously Announced $5 Million Registered Direct Offering of Common Stock and Warrants Proceeds to help fund company’s international expansion Business Wire SALT LAKE CITY -- April 15, 2013 BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the required closing of its previously announced $5.0 million registered direct offering of common stock and warrants occurred. Proceeds will be used for general working capital purposes, including to support BSD’s international expansion associated with its just announced master distribution agreement of its MicroThermX^® products in 100 countries, including Europe, Western Asia and Northern Africa and for the Company’s recently signed distribution agreement for its hyperthermia products in Taiwan. As previously disclosed, the company sold 4,065,042 shares of its common stock at $1.23 per share to two institutional investors in the registered direct offering. In addition, warrants to purchase 3,048,782 shares of common stock in the aggregate were issued to the investors. The warrants are exercisable beginning six months and one day after April 12, 2013, expire 5 years after becoming exercisable, and have an exercise price of $1.65 per share. As previously disclosed, the transaction was required to close on or before April 12, 2013. Roth Capital Partners served as the placement agent for the offering. The shares of common stock and warrants described above were offered pursuant to an effective shelf registration statement as filed with the Securities and Exchange Commission. A prospectus supplement relating to the offering was filed with the Securities and Exchange Commission on April 9, 2013. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and accompanying base prospectus can be obtained from Roth Capital Partners at 888 San Clemente Drive, Newport Beach, CA 92660, attention: Equity Capital Markets or 800-678-9147 or firstname.lastname@example.org. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information. Contact: BSD Medical Corporation William (Bill) S. Barth, 801-972-5555 fax: 801-972-5930 email@example.com
BSD Medical Closes Previously Announced $5 Million Registered Direct Offering of Common Stock and Warrants
Press spacebar to pause and continue. Press esc to stop.